Advances in type 2-high asthma therapy: what remains missing?

View Full Paper

Ask AI

Bookmark

Many patients with type 2-high asthma remain symptomatic despite five licensed biologics.
Evidence from randomized trials indicates the need for innovative solutions to overcome treatment plateaus.
Phenotype-guided biologics are replacing corticosteroids, yet uncertainties about long-term safety and costs remain.
Future advancements rely on coordination between scientific, regulatory, and economic strategies for equitable treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Evidence from various interventions shows symptoms persist in patients with T2HA, highlighting ongoing access and safety challenges.

Meslamani et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark